Neuropediatrics 2010; 41(1): 39-42
DOI: 10.1055/s-0030-1253425
Short Communication

© Georg Thieme Verlag KG Stuttgart · New York

The Cytokine and Chemokine Profiles in Rhabdomyolysis in a Patient with Gaucher Disease Type II

K. Wakusawa1 , 4 , K.  Haginoya1 , 2 , M. Ishitobi1 , N. Hino-Fukuyo1 , N. Togashi3 , I. Sato1 , T. Ohura4 , H. Yokoyama5 , M. Kikuchi6 , K. Iinuma7 , S. Tsuchiya1
  • 1Department of Pediatrics, Tohoku University, Sendai, Japan
  • 2Department of Pediatric Neurology, Takuto Rehabilitation Center for Children, Sendai, Japan
  • 3Department of Pediatrics, Eko-Ryoikuen, Sendai, Japan
  • 4Department of Pediatrics, Sendai City Hospital, Sendai, Japan
  • 5Department of Nrusing, Yamagata University, Yamagata, Japan
  • 6Department of Pediatrics, Hitachi General Hospital, Sendai, Japan
  • 7Ishinomaki Red Cross Hospital, Ishinomaki, Japan
Further Information

Publication History

received 13.11.2009

accepted 15.04.2010

Publication Date:
22 June 2010 (online)

Abstract

This report describes a patient with Gaucher disease type II who developed severe rhabdomyolysis. We treated him successfully and measured various cytokine and chemokine levels sequentially to elucidate the pathophysiology of rhabdomyolysis. The serum levels of interleukin-6, −8, −10, granulocyte colony-stimulating factor, interferon-γ, and monocyte chemoattractant protein-1 were markedly elevated in the early phase of rhabdomyolysis. These findings indicate that cytokines and chemokines are related to the massive myolysis and regenerating process. A viral infection may have triggered rhabdomyolysis through exaggerated activation of macrophages in our patient. The profiles of cytokines and chemokines should be examined in further cases to increase our understanding of the pathophysiology of rhabdomyolysis.

References

  • 1 Allen MJ, Myer BJ, Khokher AM. et al . Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-10.  QJM. 1997;  90 19-25
  • 2 Barak V, Acker M, Nisman B. et al . Cytokines in Gaucher's disease.  Eur Cytokine Netw. 1999;  10 205-210
  • 3 Febbraio MA, Pedersen BK. Muscle-derived interleukin-6: mechanisms for activation and possible biological roles.  FASEB J. 2002;  16 1335-1347
  • 4 Hollak CE, Evers L, Aerts JM. et al . Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease.  Blood Cells Mol Dis. 1997;  23 201-212
  • 5 Mannix R, Tan ML, Wright R. et al . Acute pediatric rhabdomyolysis: causes and rates of renal failure.  Pediatrics. 2006;  118 2119-2125
  • 6 Michelakakis H, Spanou C, Kondyli A. et al . Plasma tumor necrosis factor-a (TNF-a) levels in Gaucher disease.  Biochim Biophys Acta. 1996;  1317 219-222
  • 7 Mohammed I, Hussain A. Intrathecal baclofen withdrawal syndrome – a life-threatening complication of baclofen pump: a case report.  BMC Clin Pharmacol. 2004;  4 6
  • 8 Ostrowski K, Rohde T, Asp S. et al . Chemokines are elevated in plasma after strenuous exercise in humans.  Eur J Appl Physiol. 2001;  84 244-245
  • 9 Smith JA, Telford RD, Baker MS. et al . Cytokine immunoreactivity in plasma does not change after moderate endurance exercise.  J Appl Physiol. 1992;  73 1396-1401
  • 10 Stone DL, Tayebi N, Orvisky E. et al . Glucocerebrosidase gene mutations in patients with type 2 Gaucher disease.  Hum Mutat. 2000;  15 181-188
  • 11 Stratos I, Rotter R, Eipel C. et al . Granulocyte-colony stimulating factor enhances muscle proliferation and strength following skeletal muscle injury in rats.  J Appl Physiol. 2007;  103 1857-1863
  • 12 Yamin C, Duarte JA, Oliveira JM. et al . IL6 (−174) and TNFA (−308) promoter polymorphisms are associated with systemic creatine kinase response to eccentric exercise.  Eur J Appl Physiol. 2008;  104 579-586

Correspondence

Kazuhiro Haginoya

Department of Pediatric

Neurology

Takuto Rehabilitation Center for

Children

20 Shikaotsu

Akiumachi Taihakuku

982-0241 Sendai

Japan

Phone: +81-22-398-2221

Fax: +81-22-397-2691

Email: khaginoya@silk.ocn.ne.jp

    >